{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:45:08Z","timestamp":1773470708989,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy has been the standard of care for almost 20\u00a0years for locally advanced breast cancer (LABC). Sequential administration of eribulin (E) following A\/T could provide a greater response rate for women with LABC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-arm, multicenter, Phase II prospective study, the patients received 4 cycles of the FEC regimen and 4 cycles of taxane. After the A\/T-regimen, 4 cycles of E were administered followed by surgical resection. The primary endpoint was the clinical response rate. Eligible patients were women aged 20\u00a0years or older, with histologically confirmed invasive breast cancer, clinical Stage IIIA (T2\u20133 and N2 only), Stage IIIB, and Stage IIIC, HER2-negative.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A preplanned interim analysis aimed to validate the trial assumptions was conducted after treatment of 20 patients and demonstrated that clinical progressive disease rates in the E phase were significantly higher (30%) than assumed. Therefore, the Independent Data Monitoring Committee recommended stopping the study. Finally, 53 patients were enrolled, and 26 patients received the A\/T\/E-regimen. The overall observed clinical response rate (RR) was 73% (19\/26); RRs were 77% (20\/26) in the AT phase and 23% (6\/26) in the E phase. Thirty percent (8\/26) of patients had PD in the E phase, 6 of whom had achieved cCR\/PR in the AT phase. Reported grade\u2009\u2265\u20093 AEs related to E were neutropenia (42%), white blood cell count decrease (27%), febrile neutropenia (7.6%), weight gain (3.8%), and weight loss (3.8%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Sequential administration of eribulin after the A\/T-regimen provided no additional effect for LABC patients. Future research should continue to focus on identifying specific molecular biomarkers that can improve response rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-021-06396-0","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T09:07:50Z","timestamp":1632388070000},"page":"425-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)"],"prefix":"10.1007","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-3708","authenticated-orcid":false,"given":"Ippei","family":"Fukada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuki","family":"Matsunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohjiro","family":"Mashino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taijiro","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yotsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosho","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kashiwaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumasa","family":"Kuroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"6396_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","volume":"30","author":"N Wolmark","year":"2001","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96\u2013102. https:\/\/doi.org\/10.1093\/oxfordjournals.jncimonographs.a003469","journal-title":"J Natl Cancer Inst Monogr"},{"key":"6396_CR2","doi-asserted-by":"publisher","unstructured":"Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N, National Surgical Adjuvant Breast and Bowel Project Protocol B-27 (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22):4165\u20134174. https:\/\/ascopubs.org. https:\/\/doi.org\/10.1200\/JCO.2003.12.005","DOI":"10.1200\/JCO.2003.12.005"},{"key":"6396_CR3","doi-asserted-by":"publisher","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 25(28):4414\u20134422. https:\/\/ascopubs.org. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823","DOI":"10.1200\/JCO.2007.10.6823"},{"issue":"12","key":"6396_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","volume":"91","author":"AE Ring","year":"2004","unstructured":"Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91(12):2012\u20132017. https:\/\/doi.org\/10.1038\/sj.bjc.6602235","journal-title":"Br J Cancer"},{"key":"6396_CR5","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, Raab G, Caputo A, Sch\u00fctte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23(12):2676\u20132685. https:\/\/ascopubs.org. https:\/\/doi.org\/10.1200\/JCO.2005.05.078","DOI":"10.1200\/JCO.2005.05.078"},{"key":"6396_CR6","doi-asserted-by":"publisher","unstructured":"Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019\u20132027. https:\/\/ascopubs.org. https:\/\/doi.org\/10.1200\/JCO.2005.04.1665","DOI":"10.1200\/JCO.2005.04.1665"},{"issue":"5\u20136","key":"6396_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000318169","volume":"78","author":"T Taguchi","year":"2010","unstructured":"Taguchi T, Masuda N, Nakayama T, Motomura K, Tsukamoto F, Shimazu K, Nomura T, Morimoto T, Yamamoto H, Wakita K, Nakano Y, Yoneda K, Inaji H, Takatsuka Y, Noguchi S, Kinki Breast Cancer Study Group (KBCSG) (2010) Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)]. Oncology 78(5\u20136):302\u2013308. https:\/\/doi.org\/10.1159\/000318169","journal-title":"Oncology"},{"issue":"3","key":"6396_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10549-007-9744-z","volume":"110","author":"M Toi","year":"2008","unstructured":"Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y, Japan Breast Cancer Research Group (JBCRG) (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110(3):531\u2013539. https:\/\/doi.org\/10.1007\/s10549-007-9744-z","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6396_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/jnci\/djn089","volume":"100","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, K\u00fcmmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, German Breast Group (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100(8):552\u2013562. https:\/\/doi.org\/10.1093\/jnci\/djn089","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"6396_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jnci\/djn085","volume":"100","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, K\u00fcmmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, German Breast Group (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100(8):542\u2013551. https:\/\/doi.org\/10.1093\/jnci\/djn085","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6396_CR11","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.3747\/co.27.5769","volume":"27","author":"SJ Seung","year":"2020","unstructured":"Seung SJ, Traore AN, Pourmirza B, Fathers KE, Coombes M, Jerzak KJ (2020) A population-based analysis of breast cancer incidence and survival by subtype in Ontario women. Curr Oncol 27(2):e191\u2013e198. https:\/\/doi.org\/10.3747\/co.27.5769","journal-title":"Curr Oncol"},{"issue":"6","key":"6396_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","volume":"23","author":"K Aogi","year":"2012","unstructured":"Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S (2012) A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23(6):1441\u20131448. https:\/\/doi.org\/10.1093\/annonc\/mdr444","journal-title":"Ann Oncol"},{"issue":"2","key":"6396_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-016-3808-x","volume":"157","author":"K Inoue","year":"2016","unstructured":"Inoue K, Saito T, Okubo K, Kimizuka K, Yamada H, Sakurai T, Ishizuna K, Hata S, Kai T, Kurosumi M (2016) Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat 157(2):295\u2013305. https:\/\/doi.org\/10.1007\/s10549-016-3808-x","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6396_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology; College of American Pathologists (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241\u2013256. https:\/\/doi.org\/10.5858\/arpa.2013-0953-SA","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"6396_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10549-007-9744-z","volume":"110","author":"M Toi","year":"2008","unstructured":"Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y, Japan Breast Cancer Research Group (JBCRG) (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110(3):531\u2013539. https:\/\/doi.org\/10.1007\/s10549-007-9744-z","journal-title":"Breast Cancer Res Treat"},{"issue":"15_suppl","key":"6396_CR16","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1200\/JCO.2020.38.15_suppl.1016","volume":"38","author":"MC Liu","year":"2020","unstructured":"Liu MC, Hillman DW, Frith AE, Lyss AP, Weckstein DJ, Moreno-Aspitia A, Le-Lindqwister N, Isaacs C, Wender DB, Lewis DA, Cole JT, Jaslowski AJ, Rowland KM, Openshaw TH, Friday BEB, Fleming GF, Asmus E, Rogak LJ, Basch EM, Dueck AC (2020) Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC). JCO 38(15_suppl):1016","journal-title":"JCO"},{"issue":"2","key":"6396_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-015-3466-4","volume":"152","author":"J Abraham","year":"2015","unstructured":"Abraham J, Robidoux A, Tan AR, Limentani S, Sturtz K, Shalaby I, Alcorn H, Buyse ME, Wolmark N, Jacobs SA (2015) Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Res Treat 152(2):399\u2013405. https:\/\/doi.org\/10.1007\/s10549-015-3466-4","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"6396_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clbc.2018.04.001","volume":"18","author":"KA Cadoo","year":"2018","unstructured":"Cadoo KA, Kaufman PA, Seidman AD, Chang C, Xing D, Traina TA (2018) Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage human epidermal growth factor receptor 2-negative breast cancer. Clin Breast Cancer 18(6):433-440.e1. https:\/\/doi.org\/10.1016\/j.clbc.2018.04.001","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"6396_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105(10):1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488","journal-title":"Cancer Sci"},{"issue":"5","key":"6396_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molmed.2008.03.004","volume":"14","author":"N Gavert","year":"2008","unstructured":"Gavert N, Ben-Ze\u2019ev A (2008) Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 14(5):199\u2013209. https:\/\/doi.org\/10.1016\/j.molmed.2008.03.004","journal-title":"Trends Mol Med"},{"issue":"4","key":"6396_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc2620","volume":"9","author":"K Polyak","year":"2009","unstructured":"Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265\u2013273. https:\/\/doi.org\/10.1038\/nrc2620","journal-title":"Nat Rev Cancer"},{"issue":"3\u20134","key":"6396_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10555-012-9377-5","volume":"31","author":"NP Gunasinghe","year":"2012","unstructured":"Gunasinghe NP, Wells A, Thompson EW, Hugo HJ (2012) Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 31(3\u20134):469\u2013478. https:\/\/doi.org\/10.1007\/s10555-012-9377-5","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"6396_CR23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 110(6):1497\u20131505. https:\/\/doi.org\/10.1038\/bjc.2014.80","journal-title":"Br J Cancer"},{"issue":"8","key":"6396_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106131","volume":"9","author":"Z Dezs\u0151","year":"2014","unstructured":"Dezs\u0151 Z, Oestreicher J, Weaver A, Santiago S, Agoulnik S, Chow J, Oda Y, Funahashi Y (2014) Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One 9(8):e106131. https:\/\/doi.org\/10.1371\/journal.pone.0106131","journal-title":"PLoS One"},{"issue":"3","key":"6396_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-020-05563-z","volume":"180","author":"DA Yardley","year":"2020","unstructured":"Yardley DA, Peacock N, Daniel B, Anz B, Molthrop DC Jr, Shroff SK, Young R, Jankov A, Vander Woude A, Shastry M, Pasek J, DeBusk LM, Hainsworth JD (2020) Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Res Treat 180(3):647\u2013655. https:\/\/doi.org\/10.1007\/s10549-020-05563-z","journal-title":"Breast Cancer Res Treat"},{"issue":"9769","key":"6396_CR26","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06396-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T16:12:10Z","timestamp":1635696730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06396-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6396"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06396-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshinori Ito received funding from AstraZeneca, Chugai, Daiichi Sankyo, MSD and Eli Lilly. Shoichiro Ohtani received remuneration from Chugai, Pfizer, AstraZeneca and Eli Lilly. Eriko Tokunaga received remuneration from Eli Lilly, Chugai and AstraZeneca, Consultant\/advisory role from Eli Lilly, Chugai and AstraZeneca. Masahiro Kashiwaba received remuneration from Chugai and Eli Lilly. Hidetaka Kawabata received funding from Taiho, Chugai, Novartis and Daiichi Sankyo. Katsumasa Kuroi received remuneration from Kyowa-Kirin, Eisai, and Chugai. Satoshi Morita received remuneration from AstraZeneca, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, MSD, Pfizer and Taiho. Shinji Ohno received remuneration from AstraZeneca, Eisai, Pfizer, Eli Lilly and Chugai, Funding from Eisai and Taiho. Masakazu Toi received remuneration from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, AFI technologies, Luxonus, Shionogi and GL Science, Consultant\/advisory role from BMS, Daiichi-Sankyo, Eli Lilly, Terumo, Luxonus, Bertis, Kyowa-Kirin, Athenex Oncology and Kansai Medical Net, Funding from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG association, Eisai, Daiichi-Sankyo, AstraZeneca, Astelas, Shimadzu, Yakult, Nippon Kayaku, AFI technologies, Luxonus, Shionogi and GL Science. Norikazu Masuda received remuneration from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai and Takeda, Funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, Sanofi, Nippon Kayaku and Daiichi Sankyo. Ippei Fukada, Naoto Kondo, Masaya Hattori, Nobuki Matsunami, Kohjiro Mashino, Masahiko Tanabe, Taijiro Kosaka, Daisuke Yotsumoto, Kosho Yamanouchi and Masataka Sawaki declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the FDA (ClinicalTrials.gov NCT01401959) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0, , and .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}